Dr. Rampal on Investigational Agents in MPNs
In Partnership With:
Raajit K. Rampal, MD, PhD, discusses investigational agents in myeloproliferative neoplasms.
Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses investigational agents in myeloproliferative neoplasms (MPNs).
The MDM2 inhibitor idasanutlin (RG7388) is being looked at in an ongoing phase II trial (NCT03287245) to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of the agent for the treatment of patients with polycythemia vera who are resistant to or intolerant of hydroxyurea. Idasanutlin demonstrated promising preclinical and phase I clinical trial (NCT02407080) activity for this patient population, says Rampal.
In myelofibrosis, the August 2019 approval of fedratinib (Inrebic) was a revolutionary addition to the armamentarium, explains Rampal.
Other investigational compounds in myelofibrosis are currently being explored in clinical trials, concludes Rampal.
